Healthcare/Pharmaceuticals Analyst Tewari provides a preview of Neurocrine Biosciences (NBIX) Phase 2 NBI-568 Schizophrenia on an Analyst/Industry conference call to be held on August 19 at 11 am. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $167 from $164 at Canaccord
- Neurocrine price target raised to $180 from $157 at Baird
- Neurocrine price target raised to $180 from $169 at Barclays
- Neurocrine price target raised to $190 from $160 at H.C. Wainwright
- Neurocrine raises FY24 INGREZZA net product sales view to $2.25B-$2.3B